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Abstract
Background: Premature ventricular complexes (PVCs) are the most common form of
ventricular arrhythmia in the general population. While in most cases PVCs represent
a primitive phenomenon with benign behavior, in a non-negligible proportion of sub-
jects frequent PVCs may be epiphenomenon of underlying occult heart diseases,
requiring special medical attention since they have been resulted linked to increased
total and cardiac mortality. Nevertheless, PVCs themselves, when incessantly fre-
quent, may be responsible for left ventricular dysfunction in otherwise normal heart.
Aim of this narrative review is to update current knowledge on the general approach
to patients with frequent PVCs on the basis of available data, with a special focus on
the value of imaging.
Hypothesis: Routine diagnostic work-up not infrequently miss subtle concealed
arrhythmic substrate, leading to erroneously refer to such arrhythmias as to
“idiopathic”.
Methods: Literature search of PVCs articles was conducted in PubMed and Scopus
electronic database.
Results: Conflicting data arise from literature about the true clinical significance of
idiopathic PVCs. There is growing body of data providing evidence that more
advanced non-invasive imaging modalities, such as cardiac magnetic resonance, have
an incremental diagnostic and prognostic value. On the other hand, in some cases the
prognostic significance of isolated subtle myocardial structural abnormalities in
patients with PVCs, still remains area of uncertainty.
Conclusion: In selected subjects with PVCs and high-risk features for concealed
arrhythmic substrate, traditional assessment to rule out the presence of heart dis-
ease, including surface ECG and transthoracic echocardiography, should be
implemented with more advanced cardiovascular imaging modalities.
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1 | INTRODUCTION
In the vast majority of patients, premature ventricular complexes
(PVCs) arise in the absence of underlying structural heart disease
(SHD), inherited primary arrhythmia syndromes or metabolic distur-
bances. In these patients, PVCs are referred as to “idiopathic”, are usu-
ally benign in nature and do not require specific treatment. However,
in a minority of patients, idiopathic PVCs have been reported as
responsible for triggering malignant ventricular arrhythmias or, in case
of high arrhythmic burden, the development of left ventricular
(LV) dysfunction. Moreover, PVCs may be epiphenomenon of
concealed SHD, such as healed myocardial infarction, chronic myocar-
ditis and non-ischemic cardiomyopathies that may remain
undiagnosed after the initial assessment. In this setting, PVCs carry a
higher risk of adverse cardiovascular events including sudden cardiac
death (SCD).1 In the last decade, a widespread use of advanced car-
diac imaging modalities such as cardiac magnetic resonance (CMR),
have improved our diagnostic accuracy. Aim of this narrative review
was to update current knowledge on the general approach to patients
presenting with frequent PVCs, with a special focus on the value of
imaging, on the basis of available data. Published articles in English
language were initially selected by searching the following headings
on PubMed and Scopus electronic database: premature ventricular
complexes (or synonyms) and idiopathic, risk stratification, cardiomy-
opathy, cardiac magnetic resonance or ablation. Title and abstract
were preliminary screened and potentially relevant reports were then
retrieved as complete manuscripts. References lists of selected articles
were reviewed for further relevant articles. Pediatric and animal stud-
ies were excluded.
2 | EPIDEMIOLOGY
The prevalence of frequent PVCs in the general population ranges
between less than 5% to up to 30% in larger studies with a slightly
higher prevalence in males compared to females and a progressive
increase with age, being infrequent (<1%) in healthy children <11 year
old and very common (>69%) in elderly subjects >75 year old.1,2 This
variability is largely driven by the different methods used to identify
PVCs. In the prospective Atherosclerosis Risk in Communities study, a
2-minute ECG-strip documented presence of PVCs in 6% of middle-
aged adults without history of coronary artery disease while Kostis
et al. reported a 10% prevalence of more than 100 PVCs/day on a
72-hour ECG monitoring among subjects without SHD on the basis of
non-invasive and invasive screening, including heart catheterization
and coronary angiography.3,4
3 | PROGNOSIS
Data on the prognostic significance of PVCs are conflicting with sev-
eral studies reporting an increased risk of heart failure and cardiovas-
cular death while others reporting a very low incidence of major
adverse cardiac events even on very long-term follow-up.1,2,5 Several
demographic and electrocardiographic factors including male gender,
older age, PVC burden, presence of multifocal PVCs and PVC-QRS
duration have been correlated with an increased risk of adverse
events, with the main prognostic element being represented by the
presence of underlying SHD.
The wide range of criteria used to rule out the presence of heart
disease partially justifies the variability of outcomes reported in
population-based studies. Indeed, early studies relied only on medical
history, physical examination and standard ECG to define PVCs as
“idiopathic”. A recent meta-analysis summarizing the evidence from
11 population-based studies on the specific setting of frequent PVCs,
arbitrarily defined as ≥1 PVC on standard 12-lead ECG or ≥30 PVCs
on 1-hour monitoring, found a 3-fold increased risk of SCD and a
2-fold increased risk of cardiac death associated with presence of
PVCs but these conclusions should be carefully weighted considering
the lack of restrictive criteria to identify the presence of SHD in most
of the studies included in the analysis.5 Recent evidence suggests that
even a more accurate screening with surface ECG and transthoracic
echocardiography (TTE) may not be sensible enough to detect subtle
myocardial structural abnormalities.6 Indeed, when the diagnostic
work-up was implemented with CMR imaging, presence of abnormal
myocardial findings could be as high as 50%.7 Interestingly, when
PVCs were identified as truly idiopathic on the basis of accurate
screening, they no longer predicted mortality or SCD.8 Aquaro et al
reported presence of right ventricular (RV) abnormalities detected by
CMR in 126 out of 396 (32%) patients with apparently idiopathic RV
outflow tract (RVOT) PVCs. RV abnormalities were associated with a
32-fold increase risk of major arrhythmic events while only 1 event
was observed among the remaining 270 patients with normal CMR
findings. Of note, PVC burden on 24-hour Holter monitoring was nei-
ther a specific marker of concealed SHD nor a reliable predictor of
adverse outcomes.9 A potential role for risk stratification of invasive
electrophysiological testing has been recently proposed by Yokokawa
et al in a large series of patients undergoing catheter ablation (CA) of
PVCs, in which the combination of CMR myocardial abnormalities
with inducibility of sustained ventricular tachycardia (VT) at
programmed ventricular stimulation was associated with a 26-fold
increased risk of adverse outcomes compared to only a 2-fold
increased risk conferred by abnormal CMR findings alone.10 Of note,
in rare cases even truly idiopathic PVCs may be related to adverse
outcomes such as fatal arrhythmias or development of
cardiomyopathy.
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4 | MALIGNANT VENTRICULAR
ARRHYTHMIAS TRIGGERED BY
IDIOPATHIC PVCS
In patients without heart disease, the most typical form of sustained
ventricular arrhythmia initiated by PVCs is monomorphic VT originat-
ing from ventricular outflow tract. This form of sustained VT have
been reported as being benign in most cases. However, PVCs trigger-
ing threatening ventricular arrhythmias, such as ventricular fibrillation
(VF) or polymorphic ventricular tachycardia (PVT), have also been
reported in patients with normal heart.11,12 In these setting the onset
of VF seems to be related to a vulnerability of the Purkinje network
with triggering monomorphic PVCs arising from the RVOT, the papil-
lary muscles or the moderator band in up to 75% of the cases. In these
cases CA of the triggering PVC has been proved to be highly effective
in preventing VF recurrence on long-term follow-up.13 Several studies
have associated PVC-triggered VF to an history of previous
unexplained syncope in almost 80% of the cases compared to 18%-
39% of patients with RVOT PVCs and sustained VT of the same mor-
phology, making healthy subjects with PVCs and history of syncope at
particular high risk and deserving careful medical attention.12 In some
series PVCs triggering VF have been linked to a shorter coupling inter-
val but these results have not been subsequently confirmed making
substantially impossible to identify the potential malign nature of
PVCs on the basis of their coupling interval.14
5 | PVC-INDUCED CARDIOMYOPATHY
Longstanding frequent PVCs may be the cause of LV impairment in
up to 7% of cases of otherwise unexplained dilated cardiomyopathy.15
The development of LV adverse remodeling and dysfunction requires
several years before becoming clinically manifest, thus patients with
persistent frequent PVCs should be annually monitored for LV func-
tion by TTE, even if completely asymptomatic. A daily PVC burden
between 16% and 24% of all heartbeats have been associated to pro-
gressive LV dysfunction.16 However, subtle myocardial mechanical
dysfunction detected by speckle tracking echocardiography has been
reported also in patients with a PVC burden as low as 4%.17 Left
bundle-branch block (LBBB) PVC-QRS morphology and longer PVC-
QRS duration (>150 ms) as well as an epicardial origin of PVCs require
a lower arrhythmic burden to develop LV dysfunction, thus corrobo-
rating the hypothesis of mechanical dyssynchrony as the main mecha-
nism of PVC-induced cardiomyopathy.18 Accordingly, narrower PVCs
originating from endocardial sites close to the Purkinje network such
as the basal septum or left bundle branch fascicles, are rarely respon-
sible for LV dysfunction owing to the less dyssynchronous effect upon
ventricular contraction. In patients presenting with frequent PVCs and
LV dysfunction, differentiating between reversible PVC-induced car-
diomyopathy and dilated cardiomyopathy manifesting with frequent
PVCs is not always easy and typically a definitive diagnosis is possible
only on retrospective basis by demonstration of reversible LV dys-
function after effective suppression of PVCs by anti-arrhythmic drugs
(AADs) or CA.19 In this regard, several factors have been linked with
reversible cardiomyopathy after successful treatment of PVCs includ-
ing a pre-treatment PVC burden of at least 10% and absence of myo-
cardial scar detectable by late gadolinium enhancement (LGE) CMR.20
A complete recovery of LV ejection fraction is typically observed
within 4 months in patients with PVC-induced cardiomyopathy in
whom a complete suppression or at least an 80% reduction of PVC
burden is obtained.21
6 | DIAGNOSTIC WORKUP OF PATIENTS
WITH FREQUENT PVCS
6.1 | Initial evaluation
Initial patient evaluation should always include detailed clinical history
taking concerning personal and family history of inherited arrhythmic
syndromes, cardiomyopathies or SCD. While the regular consumption
of some drugs (ie, ß-agonists, thyroid hormones, amphetamines) has a
definite linkage with PVCs occurrence, this has not been established
definitively with the habitual consumption of adrenergic substances
such as caffeine, alcohol and tobacco.22 A panel of laboratory tests
may be helpful to rule out metabolic disorders potentially triggering
cardiac arrhythmias such as hyperthyroidism. Because careful evalua-
tion of surface 12-lead ECG may provide information about arrhyth-
mia substrates or triggers, diagnostic workup should routinely include
it; then, if any suspicion of SHD arises, TTE and exercise stress test
should be also considered as complementary investigations. Idiopathic
PVCs are typically related to triggered activity due to cyclic adenosine
monophosphate-mediated afterdepolarizations, are frequently mono-
morphic and originate from the right and left ventricular outflow
tracts in up to 70% of the cases, thus presenting with a LBBB QRS
morphology and an inferiorly directed frontal axis.23 Conversely, PVCs
related to SHD typically have a re-entry mechanism, are more fre-
quently multifocal and often present a RBBB QRS morphology with a
superiorly directed axis.24,25 At least in some cases ECG depolariza-
tion and repolarization abnormalities such as inverted T waves are
present and consistent with presence of wall motion abnormalities on
TTE.25,26 Exercise stress testing is pivotal in risk stratification of
patients with frequent PVCs. In a French study including more than
6000 asymptomatic middle-age men without history of SHD, frequent
PVCs during bicycle exercise testing, occurred in 2.3% of all subjects
and resulted independently associated with an increased risk of car-
diovascular death by a factor of 2.5 during long-term follow-up. Inter-
estingly, only 5.8% of patients with exercise-induced PVCs had ECG
findings suggestive for myocardial ischemia during stress.27 Eckart
et al also reported an higher prevalence of fixed-perfusion defects
consistent with past myocardial infarction or scarring among patients
with exercise-induced frequent PVCs referred for 99mTc-sestamibi
myocardial stress perfusion imaging compared to patients without
arrhythmias. Interestingly, only exercise-induced multifocal PVCs or
PVCs with RBBB morphology were associated with higher risk for
death in this series.28 In a recent CMR study, 68% of 162 patients
with exercise-induced PVCs without SHD on routine diagnostic work
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up had evidence of areas of LGE with a sub-epicardial or mid-
myocardial distribution consistent with previous myocarditis, com-
pared to only 9% of controls. Moreover, in 37% of such cases myocar-
dial oedema consistent with acute inflammatory process was also
detected.29 In a large cohort of 29 244 asymptomatic patients with-
out history SHD who underwent treadmill exercise testing, frequent
PCVs occurring during the recovery-phase (≥7 PVCs/min) were
detected in 3.7% of cases and were associated with a 2.4-fold
increase risk of death at 5-years follow-up. Of note, PVCs during
recovery-phase were a stronger predictor of increased mortality than
PVCs occurring only during exercise and resulted associated with
higher rate of myocardial ischemia during exercise-stress
echocardiography.30
6.2 | Cardiac magnetic resonance
CMR currently represents the most accurate non-invasive imaging
technique for identification and characterization of myocardial
arrhythmogenic substrate. CMR imaging is able to accurately and
reproducibly quantify biventricular volumes and function, and to char-
acterize myocardial tissue by detecting presence of myocardial fatty
replacement, myocardial oedema and necrosis/fibrosis, especially
regarding the RV structure whose subtle alterations may otherwise
remain unrecognized at initial diagnostic work up or with other imag-
ing modalities.7,31 Focal myocardial abnormalities representing the
result of local inflammatory processes (eg, healed myocarditis) or the
early manifestation of a cardiomyopathy have been described in up to
half of the patients with frequent PVCs and unremarkable ECG and
echocardiographic findings.7,24,31 Altogether, studies that have inves-
tigated CMR findings in patients with frequent PVCs have found a
pool of baseline clinical variables and arrhythmia features to be corre-
lated with presence of myocardial structural abnormalities (Figure 1).
In most of these cases CMR reveals one or more foci of non-ischemic
LGE more frequently located within the septum or the LV lateral
wall.25 The identification of subtle myocardial abnormalities has a sig-
nificant clinical impact, as they have been correlated with an increased
risk of malignant arrhythmic events during the long-term follow-up.25
Multiple studies have investigated the prognostic role of CMR imaging
in patients presenting with ventricular arrhythmias (VAs) and repeat-
edly reported presence of LGE to be an independent predictor of
adverse outcomes regardless the underlying LV ejection fraction.32
Even if the vast majority of such studies have included an heteroge-
neous population of patients with different forms of VAs (including
sustained VT/VF), similar findings, showing a relationship between
CMR features and prognosis, have been reported in few studies spe-
cifically addressing patients with isolated PVCs (Figure 2).
6.3 | Cardiac computed tomography
ECG-triggered or gated multislice CT (MSCT) represents a useful
imaging modality to non-invasively assess the origin and course of the
coronary arteries and the presence of coronary artery disease, due to
its high-spatial resolution and the capability of multiplanar reconstruc-
tions. Also, in cardiomyopathy subjects without obstructed coronary
arteries and with PVCs, MSCT is able to identify areas of myocardial
fibrosis potentially related to poor outcome.33 Advances in CT tech-
nology observed in the last decade allow also to minimize radiation
exposure. However, frequent PVCs and suboptimal heart rate control
significantly reduce the ability to acquire diagnostic datasets and
increase the risk of higher radiation dose.
6.4 | Nuclear medicine
Nuclear imaging, especially positron emission tomography (PET), is
acquiring a growing role in the management of patients presenting
with VAs. Using different tracers, PET is able to assess myocardial
perfusion, presence of inflammation, myocardial viability and
sympathetic innervation which all may have a role in the genesis and
maintenance of VAs.34 So far only two studies have applied 18F-
fluorodeoxyglucose (18F-FDG) PET to investigate the presence of sub-
clinical myocardial inflammation in patients with VAs.34 In one of
them, abnormal 18F-FDG uptake was found in up to 50% of patients
F IGURE 1 Predictors of cardiac
magnetic resonance abnormalities in
patients with apparently idiopathic
premature ventricular complexes (PVCs).
The odds-ratio of each factor is indicated
on the horizontal axis and color coded
within the circles; the area of each circle
is proportional to the numerosity of the
sample investigated. CMP:
cardiomyopathy; RBBB: right bundle
branch block; SCD: sudden cardiac death
[Correction added on 14th October 2019,
after first online publication: Figure 1
replaced with updated figure, which
includes updated references.]
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presenting with VAs and non-ischemic cardiomyopathy of unknown
etiology.35 More recently, a single center prospective study
(Myocarditis and Ventricular Arrhythmia registry—MAVERIC) includ-
ing patients with frequent PVCs and no SHD on the basis of ECG and
TTE, reported abnormal myocardial 18F-FDG uptake in 51% of
patients. Patients treated with immunosuppression due to positive
PET, demonstrated a good clinical response with a significant
decrease in PVC burden in up to 80% of the cases.34 Even if the
F IGURE 2 Forest plot showing the
results of principal studies investigating
the risk of major adverse cardiovascular
events associated with the presence of
myocardial structural abnormalities
detected by cardiac magnetic resonance
in patients with apparently idiopathic
ventricular arrhythmias [Correction added
on 14th October 2019, after first online
publication: Figure 2 replaced with
updated figure, which includes updated
references.]
F IGURE 3 Proposed flow-chart for the diagnostic work-up and management of patients presenting with apparently idiopathic premature
ventricular complexes (PVCs). Careful evaluation of personal history, baseline electrocardiogram (ECG) and PVC features should be always the
first step in the diagnostic work-up of patients with frequent PVCs (left panel); complementary diagnostics may be needed to rule out suspected
causes of PVCs (eg, valvular or ischemic heart disease). When features suggestive of truly idiopathic PVCs are present (central panel, green
triangle), no further investigations are mandatory. Conversely, when one or more high-risk features (central panel, red triangle) are present,
further investigations with advanced imaging techniques should be considered in order to detect possible underlying structural abnormalities
deserving proper medical attention and specific treatment (right panel) CMP: cardiomyopathy; CT: computed tomography; FDG-PET:
fluorodeoxyglucose positron emission tomography; LBBB: left bundle branch block; LV: left ventricle; NSVT: non-sustained ventricular
tachycardia; RBBB: right bundle branch block; SCD: sudden cardiac death; SHD: structural heart disease; TT: transthoracic
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above data seem promising, the application of 18F-FDG PET in daily
clinical practice as well as the decision to treat patients with immuno-
suppression should be carefully weighted and needs further validation
by randomized controlled studies.
When an accurate initial evaluation process detects high-risk fea-
tures, thus raising suspicion of concealed SHD, the use of advanced
cardiovascular imaging techniques (eg, CMR, MSCT, PET) should be
considered. The flow-chart in Figure 3 offers an easy-to-consult
graphic model to orientate the decision-making process throughout a
comprehensive diagnostic work-up and management of patients pre-
senting with frequent PVCs.
6.5 | Genetic testing in idiopathic PVCs
Current guidelines recommend genetic testing in patients with VAs
and/or aborted SCD or in family members of SCD victims when an
inheritable arrhythmogenic disease is suspected.36 No specific rec-
ommendations are currently known for genetic testing in patients
with idiopathic PVC unless clinical features and family history raise
the suspicion of an inherited arrhythmic disorder. In the last few
decades, genetic testing for channelopathies and cardiomyopa-
thies had advanced from initial scientific discoveries to clinical
application in daily clinical practice. Therefore, genetic information
may support a suspected clinical diagnosis of the proband, offering
a cascade screening of family members when a disease-causing
mutation is identified.37 It is important to highlight that genotyping
have a direct diagnostic, prognostic and therapeutic implication
only in some cases such as long QT syndrome while in other disor-
ders such as Brugada syndrome, it does not provide additional clin-
ical information for the proband. In these setting, genotyping is
mostly useful for family screening of a mutation-positive proband
to identify gene positive relatives in a preclinical phase allowing
the introduction of lifestyle changes or therapies. On the other
hand, genotype-negative family members may be dismissed from
periodic follow up.37
6.6 | Therapy: when and how to treat
idiopathic PVCs
In the majority of cases, idiopathic PVCs are a benign clinical con-
dition with a good prognosis and a specific treatment is usually
unnecessary. The 2014 EHRA/HRS/APHRS Expert Consensus on
VAs suggests, as first step, reassurance about the benign nature of
this arrhythmia allaying patients' anxiety.38 In case of highly symp-
tomatic patients, significant PVCs burden (with or without symp-
toms) or suspicion of PVC-induced cardiomyopathy, a therapeutic
intervention is recommended. AADs are commonly used as a first-
line option even though no large-scale randomized trials on AAD
therapy for idiopathic PVCs have been performed.39 Usually beta-
blockers or non-dihydropyridine calcium antagonists are consid-
ered as first-line therapy but their efficacy is quite limited, being
similar to placebo, and the occurrence of side effects are not infre-
quent, thus reducing patient's compliance. While Class I AADs are
highly effective to suppress PVCs and improve symptoms, the risk-
benefit ratio has not yet been carefully evaluated in patients with-
out underlying cardiomyopathy. Multiple studies indicate high effi-
cacy of CA with PVC elimination in 74%-100% of patients
associated with low complication rate (about 1%). The only pro-
spective randomized study comparing CA and AADs confirmed the
superiority of the ablative approach in preventing arrhythmia
recurrences, at least in patients with PVCs originating from
RVOT.39 Indeed, CA success is strongly related to the PVCs site of
origin with RVOT-PVCs being the most easily approachable. Idio-
pathic PVC origins different from RVOT, such as LVOT, aortic cusp
or epicardial origins or multiple morphologies, have been demon-
strated to be associated with a lower success rate and with a trend
toward the highest complication rate.40 The recent 2019
HRS/EHRA/APHRS/LAHRS Expert Consensus on CA of VAs, rec-
ommends CA of idiopathic PVCs in patients with symptomatic
PVCs originating from RVOT as first line therapeutic approach in
preference to AAD therapy.41 In patients with symptomatic PVCs
originating from other sites than RVOT (including LVOT, epicardial
OT or LV summit) or in those presenting with polymorphic PVCs,
CA can be considered only after failed/not tolerated medical ther-
apy or when patients refuse taking drugs.41
Owing to the benign nature of truly idiopathic PVCs, implantable
cardiac defibrillators are not recommended. However, it should be
considered in patients with persistent LV dysfunction after a reason-
able waiting period of 4-6 months following efficacious AAD or abla-
tive treatment, according to the current guideline recommendations
for primary prevention of SCD in heart failure.
6.7 | Economic and organizational issues
Whether all patients with frequent PVCs and apparently normal
heart by routine diagnostic tests deserve further investigation with
more advanced imaging modalities (eg, CMR imaging) is still
unclear. This issue needs to take into account several aspects,
including lack of widespread availability and direct and indirect
costs of these technologies, reimbursement and sustainability for
the healthcare system, needs for appropriate training and educa-
tion. Identification of those subjects who may benefit most from
further investigations appears therefore relevant. Previous studies
have identified older age, male gender, family history of
SCD/cardiomyopathy and few PVC features (Figure 1) as signifi-
cantly and independently correlated to the presence of myocardial
structural abnormalities by CMR imaging; these baseline character-
istics could be proposed as “red flags” to identify those subjects
with apparently idiopathic PVCs that may conversely have
concealed cardiomyopathic substrates and therefore get the
higher benefit from a more comprehensive diagnostic work-up
inclusive of CMR imaging. Organization of a network for referral of
patients to high-volume centers with the adequate equipment and
expertise for advanced imaging should be also encouraged.
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7 | CONCLUSIONS
Even if benign in nature in the vast majority of cases, PVCs can some-
times be associated with an increased risk of heart failure and cardiac
mortality including SCD. The main challenge in correctly labelling
PVCs as benign is the exclusion of subtle myocardial structural abnor-
malities that can be missed by routine investigations. Thus, in selected
subjects with high-risk features, traditional assessment should be
implemented with more advanced imaging modalities such as CMR.
On the other hand, the use of more sensitive technologies might rise
additional interpretative doubts especially when subtle or isolated
myocardial structural abnormalities (eg, fibrosis) are documented in
patients with PVCs but without any symptoms or evidence of more
complex VAs. As a matter of fact, at least in some cases, subtle myo-
cardial scarring may be an incidental finding (eg, healed myocarditis)
without any meaningful relationship with PVC etiology (ie, RVOT
PVCs). In such cases, the interaction between PVCs and the potential
arrhythmic substrate remains uncertain with a substantial knowledge
gap regarding proper risk stratification (eg, invasive electrophysiologi-
cal study) and therapy.
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